These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 25509362

  • 1. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 17; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 4. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 5. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 29; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 6. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct 29; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 7. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 29; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH, Moraes L, Fink MC, Callegaro D, Romano CM, Oliveira AC.
    Arq Neuropsiquiatr; 2014 Dec 29; 72(12):960-5. PubMed ID: 25465776
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 10. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 29; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 11. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 29; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 12. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 29; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 13. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC.
    Mult Scler; 2014 May 29; 20(6):757-60. PubMed ID: 24189572
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C, Montalban X.
    CNS Drugs; 2014 Jul 29; 28(7):641-8. PubMed ID: 24942634
    [Abstract] [Full Text] [Related]

  • 15. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 29; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov 29; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 17. Advances in the management of PML: focus on natalizumab.
    Fox R.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [Abstract] [Full Text] [Related]

  • 18. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D, Rossi S, Rinaldi F, Gallo P.
    Neurology; 2012 Nov 06; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract] [Full Text] [Related]

  • 19. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 06; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 20. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.
    PLoS Pathog; 2012 Jun 06; 8(11):e1003014. PubMed ID: 23144619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.